DexCom Inc (DXCM) Quote

Why is nobody talking about $TRIB. Trinity Biotech recently purchased DexCom Incs technology. $TRIB is a hidden gem

https://www.webcaster4.com/Player/Index?webcastId=41975&g=5ff46fae-ca0b-4696-b3a4-4a64d6dfc159&uid=3737459&sid=

I will

You think sens will disrupt, check out KNWN. They have not only a breakthrough platform for numerous non-invasive medical applications but the 60+ patents to secure their success.

SuperBowl commercial will reach huge multi million viewer audience to both educate about CGM, make Dexcom better known to potential audience and is part of "direct to consumer" or significantly ramped up DTC marketing program in preparation for the launch of G7 device later this year. If you check the job websites like LinkedIn,Indeed and monster.com you can see that huge hiring ramp of over 150 spots to increase manufacturing shifts in Arizona, add more detail teams to call on pharmacies and support additional future R&D efforts. The 12 months 8/21 to 8/22 are going to be explosive IMHO.

Get in below a buck? Yep I'd love to do that but......maybe another stock?

Upcoming presentation at update at JPMorgan Healthcare Conference may be a catalyst

I think it’s bc sens will disrupt that sector superior product 6 month product that is superior period. If you missed dxcm get in sens cause it makes cents to be in here below a buck

BREAKING NEWS: $DXCM Why Is No One Talking About DexCom Stock?

Glucose monitor maker DexCom (NASDAQ: DXCM) has had a rough month. After a Wall Street analyst downgraded the stock Oct. 2 and sharply trimmed its price target, the price fell over the next 30 days, with the majority of the downward movement taking place in the last week of Octo...

Got this from DXCM - Why Is No One Talking About DexCom Stock?

Just In: $DXCM Why I Just Bought These 2 Under-the-Radar Stocks

Last week, I bought shares of Dexcom (NASDAQ: DXCM) and Inari Medical (NASDAQ: NARI) . But while it's obvious to me that Dexcom is an incredibly successful stock, having run up almost 3,400% since its IPO 15 years ago, it still hasn't garnered a lot of investor attention. ...

Got this from DXCM - Why I Just Bought These 2 Under-the-Radar Stocks

what was reason for Wells Fargo analyst downgrade today?

Hmmm, probably whether you got in at $50 or $500 might influence you feelings these days... Great company, product, and big PPS.

The share price is supposed to go up.

I want a refund on my investment!

Trueheart

CNBC's Joshua Brown discussed DXCM today. He said it was priced high but given the need for its products he blessed it, along with other companies that produce medical devices. He mentioned Japan, Europe and America as being great markets.

He was asked if the stock was too high and his reply was it had a long runway and wouldn't bet against it.

Zounds!

Truehea

The beauty of DexCom is that it's growing because Americans are growing --- in size.

Diabetes is rampant and fat people continue to eat and seem not to give a damn that the disease is killing them slowly.

Onward and upward!

Trueheart

News: $DXCM Could DexCom Be a Millionaire-Maker Stock?

Winners tend to keep on winning. And make no mistake about it:  DexCom (NASDAQ: DXCM) is a winner. During its 21 years in business, the medical-device maker has transformed how individuals manage diabetes. DexCom's market cap now stands at close to $40 billion. The company generated nea...

Got this from DXCM - Could DexCom Be a Millionaire-Maker Stock?

Motley Fool just recommended DXCM today.

Not too big to avoid strategic acquisition by a Lilly or Johnson & Johnson

Wow, another 30% up. A winner that keeps on producing.

Great day here today...must be good news coming.

Nmrd has just recieved CE mark for sugar beat device , non invasive wireless CMG

Bought into this at 60 way back an still holding it. Hoping for split, never know peeps, $$$$$ patience

AAC, in New Orleans this coming weekend, has as one of its featured breakthrough presentations "the Apple Watch". We own DXCM shares here too, as well as AAPL shares.

I use their G6 and it is great product. Their customer service is one of the worst ever. Now, they are outsourcing it overseas where they know nothing about it? Geez.

Wow, outstanding Q and prospects for the rest of the year and beyond!

DXCM: Normal for diabetics.

https://www.webmd.com/diabetes/guide/normal-blood-sugar-levels-chart-adults

Just keeps climbing- nice

Short

Short

Great news for both the company and the world of diabetics!

DXCM: The reason:

http://ih.advfn.com/p.php?pid=nmona&article=77048172

Moving north very nicely....looking good!

HENDERSON GROUP PLC has filed a new 13G, reporting 10.2% ownership in $DXCM - https://fintel.io/i/henderson-group and https://fintel.io/i/henderson-group

fillin the gap..

DXCM RSI 5

DXCM RSI 5

....and now this ...

Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment"...

zagdad

Huge news for DexCom, its shareholders, and the patients in need IMHO.

zagdad

http://finance.yahoo.com/news/fda-approval-dexcom-non-adjunctive-210100548.html

NO MEDICARE COVERAGE YET.

DXCM DAY

As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place of standard daily finger-stick blood testing.

Dexcom wants regulatory approval so that the information gathered by the device from a patient could be used to administer insulin without the standard fingerstick-based blood reading. If approved by the agency, analysts have said Dexcom could eventually garner Medicare coverage and grow the use of its device by as much as 23%.

The Clinical Chemistry and Clinical Toxicology Devices Panel, which met Thursday, voted 8-2 to support that there is reasonable assurance that the G5 Mobile CGM system is safe for the proposed indications for use.

It voted 9-1 that there is reasonable assurance that the device is effective for the proposed indications for use, and in an 8-2 vote, supported the benefits of the G5 Mobile CGM system outweighed the risks for the proposed indications for use.

"This recommendation is a big milestone for people with diabetes," Kevin Sayer, DexCom’s president and CEO, said in a statement, “We commend the FDA for bringing this important subject into a public forum, and thank the panel members, as well as the public speakers for their willingness to participate.”

Still, there was some concern before going into the panel review. Those concerns centered on the heavy reliance of data from computer simulation studies and the limitations of the human factor studies conducted by Dexcom, according to a review by Jefferies, a securities firm that rates Dexcom shares a buy.

Additional discussion at the review focused on how a majority of CGM patients already make dosing decisions based on information gathered by the devices and there might need to be appropriate training, which is only possible by a labeled indication. It was suggested by the panel that training instructions be detailed on the label itself.

Perhaps one of the key takeaways is that the regulatory agency and Dexcom remain in discussions about a post-marketing study design, which will have to be locked down before final FDA approval is granted. Wall Street analysts believe the final decision on that study could establish a clinical standard that all other devicemakers will need to meet if they want to secure a dosing claim for their own CGMs.

Dexcom management will hold a conference call to discuss the meeting starting at 8:30 a.m. (Eastern Time) on Friday, July 22 2016.

To listen to the conference call, please dial (888) 771-4371 (US/Canada) or (847) 585-4405 (International) and use the confirmation number "430 195 42" approximately five minutes prior to the start time.

The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and then “Events and Webcasts,” and will be archived there for future reference

DexCom Inc. (DXCM) Halted due to pending news

July 21,
2016 07:00 AM ET
Dow Jones Newswires

$DXCM Daily and Weekly Ichimoku Chart

DXCM - what's going on here today? Anybody a close follower?

Thx, zagdad

echo pharmaceuticals on the fringe of non invasive CGM for diabetes. This could be a major break through which would hurt DXCM future growth. I do not know the particulars but their is a big buzz that they are near the clinical testing stage. How is it that DXCM has not developed a non invasive CGM system. If I was a diabetic I wouldn't want to prick my finger or draw blood on a daily bases. Does anyone have any insight regarding DXCM having a non invasive CGM or on Echo thereapeutics.

DXCM Conference Call

Management will hold a conference call as previously scheduled on November 4, 2015 starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived for future reference. To listen to the conference call, please dial (888) 771-4371 (US/Canada) or (847) 585-4405 (International) and use the confirmation number "40455195" approximately five minutes prior to the start time.

8% revenue beat and bullish comments make DXCM very enticing at these prices.